Overview

Study of the Bioequivalence of Two Tablet Forms of MK0431 (0431-027)

Status:
Completed

Trial end date:
2004-11-01

Target enrollment:

Participant gender:

Summary

This study will establish that the MK0431 100 mg anhydrous formulation tablets are bioequivalent to the MK0431 100 mg monohydrate final market image (FMI) tablets.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Sitagliptin Phosphate